AMP: Single arm, phase I/II study to evaluate the six month progression free survival of AMG 102 and panitumumab in recurrent Glioblastoma Multiforme (GBM)

Trial Profile

AMP: Single arm, phase I/II study to evaluate the six month progression free survival of AMG 102 and panitumumab in recurrent Glioblastoma Multiforme (GBM)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Panitumumab (Primary) ; Rilotumumab (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top